Sandoz Recalls Orphenadrine Citrate Due to Nitrosamine Impurity
March 22, 2022
Sandoz Inc. issued a recall of 13 lots of Orphenadrine Citrate 100 mg Extended Release (ER) tablets to the consumer level due to the presence of a nitrosamine impurity. Orphenadrine is used as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Nitrosamines are substances with carcinogenic properties – which could cause cancer.
